VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundación EPIC
• Treatments: Clopidogrel

Criteria

Inclusion Criteria:

• Patients with age 18 years or above.

• Patient is able to understand the nature of study and has provided written informed consent.

• Patients with Acute Coronary Syndrome and who underwent PCI during the admission, who have been discharged on double. antiplatelet therapy with Acetylsalicylic Acid and Ticagrelor or Prasugrel.

Exclusion Criteria:

• Patients with history of intracranial bleeding.

• Patients with contraindication for the use of Acetylsalicylic Acid or Clopidogrel or Ticagrelor or Prasugrel.

• Patients with major ischemic or hemorrhagic events during the first month.

• Patients with Thrombocytopenia <50,000 /µL.

• Patients with permanent oral anticoagulation.

• Patient is pregnant or breast feeding.

• Patients with impossibility to complete 1 year of follow-up.

• Patient´s life-expectancy is less than 24 months.